Gadolinium-based contrast agents for sensitive detection of Zn
In some aspects, the present disclosure provides novel ligands, which may be used to make novel MRI contrast agents for the detection of zinc. In further aspects, by the present disclosure also provides methods of using as imaging agents and compositions thereof.
1. A compound of the formula:
wherein:
A1, A2, A3, and A4 are each independently alkanediyl (C≤12) or substituted alkanediyl (c<12) ; and
R 1 , R 2 , R 3 , and R 4 are each independently hydroxy, or
provided at least one R 1 , R 2 , R 3 and R 4 is
wherein:
X 1 and X 2 are each independently heteroaralkyl (C≤12) or substituted heteroaralkyl (C≤12) ;
provided that at least one of A1, A2, A3, or A4 is not —CH 2 —;
or a metal complex, a deprotonated form, or a salt thereof.
2. The compound of claim 1 , wherein the compound is further defined as:
wherein:
n 1 , n 2 , n 3 , and n 4 are 1, 2, 3, 4, 5, 6, 7, or 8; and
X 1 and X 2 are each independently selected from heteroaralkyl (c≤12) or substituted heteroaralkyl (C≤12) ;
provided that at least one of n 1 , n 2 , n 3 , and n 4 are not 1;
or a metal complex, a deprotonated form or a salt thereof.
3. The compound of claim 1 , wherein the compound is further defined as:
wherein:
n 1 , n 2 , n 3 , and n 4 are 1, 2, 3, or 4; provided that at least one of n 1 , n 2 , n 3 , and n 4 are not 1; and
x 1 , x 2 , x 3 , and x 4 are 1, 2, 3, or 4;
or a metal complex, a deprotonated form, or a salt thereof.
4. The compound of claim 1 , wherein the compound is a metal complex and further comprises a metal ion chelated as defined by the formula:
wherein:
A 1 , A 2 , A 3 , A 4 , R 1 , R 2 , R 3 , R 4 are as defined above; and
M is a metal ion;
or a deprotonated form or a salt thereof.
5. The compound of claim 4 , wherein M is Mn 2+ , Mn 3+ , or a lanthanide ion.
6. The compound of claim 1 , further defined as a metal complex of the formula:
or a deprotonated form or a salt thereof.
7. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
8. A method of imaging a patient comprising the steps of:
a) administering to the patient a compound of claim 1 ; and
b) obtaining an imaging scan of the patient.
9. The method of claim 8 , wherein the collected imaging scan is from an MRI.
10. The method of claim 8 , further comprising analyzing the imaging scan.
11. The method of claim 8 , wherein analyzing the imaging scan produces a diagnosis of a disease.
12. A method of imaging the pancreas in vivo in a patient to determine the onset of β-cell degeneration comprising the steps of:
a) administering to the patient a compound of claim 1 ;
b) obtaining an imaging scan of the patient; and
c) determining the presence of Zn 2+ ions.
13. The method of claim 12 , wherein the imaging scan is from an MRI.
14. The method of claim 12 , wherein the onset of β-cell degeneration indicates the onset of diabetes mellitus.
15. A method of imaging the prostate in vivo in a patient to determine the presence of a prostate tumor comprising the steps of:
a) administering to the patient a compound of claim 1 ;
b) obtaining an imaging scan of the patient; and
c) determining the presence of Zn 2+ ions.
16. The method of claim 15 , wherein the imaging scan is from an MRI.